Skip to content

    Cancer Health Center

    Font Size
    A
    A
    A

    Chronic Myelogenous Leukemia Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (05 / 23 / 2014)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

    Chronic-Phase Chronic Myelogenous Leukemia (CML)

    Recommended Related to Non-Hodgkin's Lymphoma

    Understanding Non-Hodgkin Lymphoma -- Symptoms

    Symptoms of non-Hodgkin lymphoma may include: Painless swelling of one or more lymph nodes, with no recent infection. Swelling may be intermittent. Swelling, fluid accumulation, or pain in the abdomen. Shortness of breath, wheezing, or coughing. Bloody stool or vomit. Swelling of the face, neck, and arms. Blockage of urine flow. Bone pain. Unexplained weight loss amounting to 10% of body weight over six months. Fever lasting for at least 14 consecutive days, usually in...

    Read the Understanding Non-Hodgkin Lymphoma -- Symptoms article > >

    Added text to state that nilotinib-treated patients had a lower rate of treatment-emergent BCR/ABL mutations than did imatinib-treated patients (cited Hochhaus et al. as reference 8).

    Added text to state that a single-center, retrospective analysis of 483 patients with chronic phase CML who were treated with imatinib, dasatinib, or nilotinib indicated that patients who have better than 35% t(9;22)+ cells at 3 months of therapy have inferior event-free, transformation-free, and overall survival rates compared with patients who have better early cytogenetic responses (cited Jain et al. as reference 23).

    Added Tyrosine kinase inhibitor-resistant CML as a new subsection.

    Relapsing Chronic Myelogenous Leukemia (CML)

    Added Jain et al. as reference 4.

    Added text to state that for patients resistant to the tyrosine kinase inhibitors, omacetaxine mepesuccinate has shown a hematologic response rate of 67% and a median progression-free survival of 7 months in a small, phase II study of 46 patients (cited Cortes et al. as reference 21 and level of evidence 3iiiDiv).

    This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http:// cancer .gov or call 1-800-4-CANCER.

    WebMD Public Information from the National Cancer Institute

    Last Updated: May 28, 2015
    This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
    1
    Next Article:

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
     
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article